GlassScriptPhysician profile
Pamela J Bartell
NPI 1356638860
$6,487.85
in general payments reported to CMS, 2019-2025
43 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $871 · 2021: $1,293 · 2022: $950 · 2023: $892 · 2024: $816 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.78 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,763.12 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $533.82 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $449.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $431.51 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $413.51 | 2019-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.74 | 2019-2025 | Jardiance |
| Pfizer INC. | $287.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $238.98 | 2019-2023 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $218.15 | 2019-2023 | Trintellix |
| Allergan, INC. | $200.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $172.37 | 2019-2023 | Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.35 | 2020-2025 | Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $112.34 | 2023-2025 | Inspire |
| Currax Pharmaceuticals LLC | $105.38 | 2020-2023 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $105.14 | 2019-2025 | Ajovy |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Bartell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.